[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cancer-head-neck\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cancer-head-neck":67},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100511011","single-and-combined-modality-trans-oral-robotic-surgery-in-early-oropharyngeal-cancer-100511011",false,"NCT05933889","Single and Combined Modality Trans-Oral Robotic Surgery in Early Oropharyngeal Cancer","Single and Combined Modality Trans-Oral Robotic Surgery in Early Oropharyngeal Cancer: Exploring the Impact of Surgical Margins on Local Disease Recurrence: The SCORE Study","SCORE","Inclusion Criteria:\n\n* 18 years and older.\n* Primary tumour within the oropharynx (defined as tonsil, soft palate, tongue base, lateral and posterior oropharyngeal walls)\n* Histologically confirmed squamous cell carcinoma.\n* P16 positive or negative tumours\n* Index cancer treated with TORS with or without adjuvant therapy.\n* Early pT1-T2 stage oropharyngeal SCC\n* TORS performed on or before 31st December 2021\n\nFor the exploratory analysis only:\n\n* Ability to consent to molecular analysis study\n* Ability to consent to radiomic\u002F imaging study (as required for international centres)\n\nExclusion Criteria:\n\n* Moderate to advanced stage T3-T4 oropharyngeal SCC\n* TORS performed for diagnostic, recurrent, or palliative intentions.\n* Prior history of head and neck cancer or radiation therapy at any time\n* Known distant metastatic disease.\n* Nasopharyngeal, thyroid, cutaneous, and non-SCC head and neck cancers.","ALL","18 Years",{"count":20,"type":21},250,"ESTIMATED","OBSERVATIONAL","Multi-centre retrospective observational cohort study with optional exploratory radiomic study (international) and prospective molecular analysis studies (UK only).",[25],"Cancer Head Neck",[27,28,29,30,31],"Robotic Surgical Procedures","Margins of Excision","Oropharyngeal neoplasms","Local neoplasm recurrence","Recurrence free survival","RECRUITING","2024-08-06",{"date":35,"type":36},"2024-08-07","ACTUAL",{"date":38,"type":36},"2023-12-19",{"date":40,"type":21},"2027-08",{"name":42,"class":43},"Royal Marsden NHS Foundation Trust","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":66},"100489434","archery---artificial-intelligence-based-radiotherapy-treatment-planning-for-cervical-head-and-neck-and-prostate-cancer-100489434","NCT05653063","ARCHERY - Artificial Intelligence Based Radiotherapy Treatment Planning for Cervical, Head and Neck and Prostate Cancer","Inclusion Criteria:\n\n1. Consecutive patients with histologically confirmed head and neck cancers of the oropharynx, larynx, hypopharynx and nasopharynx (Stage I-III) that have given consent for radical radiotherapy.\n2. Consecutive histologically confirmed primary cervical cancer patients (Stage IB-IIIB including pelvic node positive) that have given consent for radical radiotherapy.\n3. Consecutive histologically confirmed primary prostate cancer patients (T1-4N0M0) that have given consent for radical radiotherapy.\n4. Mental capacity to understand and consent to participate in the study.\n5. Patients aged ≥18years.\n\nExclusion Criteria:\n\n1. Patients requiring radiotherapy after curative surgery or surgery that is intended to remove as much of the tumour as possible.\n2. Patients receiving palliative radiotherapy\n3. Patients aged \\\u003C 18years.",{"count":52,"type":21},990,"The aim of this study is to look at whether an Artificial Intelligence (AI) based computer program can automate two components of the radiotherapy treatment pathway to a sufficient quality standard to enable its routine clinical use. The two components include the delineation (outlining) of anatomical areas that are at risk of tumour spread and at risk of radiation damage, and the definition of the position, size and shape of the radiation beams.\n\nThe AI-based computer programs have been developed to perform tasks that would normally require direct human involvement by oncologists and medical physicists. Proposed advantages include improved treatment accuracy, as well as a reduction in the time (from weeks to minutes) and human resources needed to deliver radiotherapy, which this study will test.",[55,25,56],"Cancer of Prostate","Cancer Cervix","2024-05-20",{"date":59,"type":36},"2024-05-22",{"date":61,"type":36},"2023-12-07",{"date":63,"type":21},"2026-09-01",{"name":65,"class":43},"University College, London",6,"Cancer Head &Neck"]